They identified 5719 youth who were prescribed any GLP-1 medication, including semaglutide, lixisenatide, albiglutide, liraglutide, exenatide, tirzepatide, or dulaglutide. They identified 23,700 ...

Rybelsus (semaglutide) is the first GLP-1 agonist drug that can be dosed orally, and is Novo Nordisk's third drug in the class after daily injectable Victoza (liraglutide) and weekly shot Ozempic ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine. Semaglutide ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

He claimed the new amendment in the Waqf Act, passed by Parliament last month, violates the landmark Kesavananda Bharati judgment by the Supreme Court, which laid down the "basic structure ...

Semaglutide has already been approved to treat type 2 diabetes under the brand name Ozempic, and to treat obesity as Wegovy. © Michael Siluk/UCG/Universal Images ...

A confirmatory secondary endpoint at Week 72 showed 32.7% of patients treated with semaglutide 2.4 mg achieved both resolution of steatohepatitis and improvement in liver fibrosis compared to 16.1 ...

Semaglutide cut inflammation in two thirds ... mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics.

semaglutide – used in Wegovy – comes off patent in some markets in 2025. Several companies are planning to launch cheaper generic versions of the drugs. Liraglutide, the active ingredient in ...

semaglutide - used in Novo's Wegovy - comes off patent in some markets next year. Several companies are planning to launch cheaper generic versions of the drugs then. Liraglutide, the active ...